CYRX · CryoPort, Inc. · Stock research

Current Thesis

Cryoport is the cold-chain toll layer on cell & gene therapy — cryogenic logistics, biostorage and packaging that bills the CGT pipeline regardless of which therapy wins. The binary the prior read was waiting on has come and gone, and it split. At the 2026-08-06 Q2 print, revenue was $49.0M (+8% YoY from $45.5M), beating the $48.21M consensus; adjusted EPS of -$0.20 missed the -$0.19 estimate; FY2026 revenue guidance was affirmed at $192–196M against a $194.39M consensus; and adjusted EBITDA from continuing operations crossed to +$0.4M from -$0.9M a year earlier. The line that powered the 2026 re-rate cracked at the same time: revenue from commercially approved CGT grew 9% YoY to $9.4M, against +26% YoY to $9.1M at the 2026-05-04 Q1 print. So the leg on offer today is the profitability crossover, not top-line acceleration. Sell-side leaned in anyway — BTIG lifted its target from $17 to $25 on 2026-07-24, Needham to $19 and Guggenheim to $16 on 2026-08-07, all Buy-maintained — while the stock closed $15.12 on 2026-08-07, 8.8% under the $16.57 52-week high, RSI(14) at 43.5. A beat plus two same-day target raises produced no new high. That combination, plus a three-month vacuum before the next scheduled print, is what the price has to work through.

Bullish and bearish views on CryoPort, Inc.

The model's bull view on CryoPort, Inc. (CYRX), in brief: Adjusted EBITDA from continuing operations turned positive at +$0.4M in Q2 2026 versus -$0.9M in Q2 2025 (press release, 2026-08-06) — a $1.3M YoY swing, and the first quarter delivering the profitability inflection management had pointed to for 2H 2026. The bear view: Commercial CGT revenue decelerated to +9% YoY ($9.4M, Q2, 2026-08-06) from +26% YoY ($9.1M, Q1, 2026-05-04). Both cases follow in full.

Bull Case

• Adjusted EBITDA from continuing operations turned positive at +$0.4M in Q2 2026 versus -$0.9M in Q2 2025 (press release, 2026-08-06) — a $1.3M YoY swing, and the first quarter delivering the profitability inflection management had pointed to for 2H 2026.
• Revenue $49.0M beat the $48.21M consensus (2026-08-06). Life Sciences Services grew 15% YoY to $28.0M, led by BioStorage/BioServices +25% YoY.
• FY2026 guidance affirmed at $192–196M (2026-08-06). The specific downside the prior note named — a guide cut — did not happen; the band is unchanged from 2026-05-04.
• Funnel expanded: 779 global clinical trials supported at 2026-06-30 versus 728 at 2025-06-30, including 94 Phase 3 programmes and 22 commercially approved therapies. Management flagged 11 possible BLA/MAA applications and up to five additional approvals for the balance of 2026 (2026-08-06).
• Cash, cash equivalents and short-term investments of $396.7M at 2026-06-30 (Q2 release) — the company is not funding the ramp from the equity market at these levels.
• Sell-side re-rated upward into and after the print: BTIG $17 → $25 on 2026-07-24, citing healthier CGT and MVE end-markets and high-teens BioLogistics/BioStorage growth; Needham $19 and Guggenheim $16 on 2026-08-07. Prior consensus was $15.11 as of 2026-07-08.
• New product cycle continues: the MVE Fusion 811 self-regenerating cryogenic freezer (no liquid-nitrogen refills) launched during Q2; management reiterated upper-single-digit Products growth for FY2026 on the 2026-08-06 call.
• Long-term trend intact: the 200-day moving average near $11.07 was reclaimed on 2026-07-11, and the three-month return through 2026-08-07 is +11.2%.

Bear Case

• Commercial CGT revenue decelerated to +9% YoY ($9.4M, Q2, 2026-08-06) from +26% YoY ($9.1M, Q1, 2026-05-04). That is the exact deceleration the prior published read named as a thesis-break condition, and it printed below the +15% threshold.
• Life Sciences Products revenue was $21.0M, flat YoY (2026-08-06). Roughly 43% of the revenue base grew zero, and the reiterated upper-single-digit FY target now needs a 2H step-up that has not been evidenced.
• Adjusted EPS -$0.20 missed the -$0.19 estimate; gross margin was 46.6% versus 47.0% in Q2 2025.
• Guidance was affirmed, not raised, against a $194.39M consensus — the print gave the model no new upside anchor.
• Price did not confirm: closed $15.12 on 2026-08-07 with RSI(14) 43.5, still 8.8% below the $16.57 52-week high set in early June, despite the 2026-07-24 BTIG raise and two more targets moving up on 2026-08-07.
• Insider distribution from the June high remains unrecovered: CFO Robert Stefanovich sold 169,427 shares at a weighted $16.27 on 2026-06-04 (~$2.76M, roughly 61% of his holding, 109,850 shares remaining), with Zecchini and Mandalam also selling in that window. Nine weeks later the stock has not traded back to those levels.
• Target dispersion is wide — Jefferies $13.50 (2026-06-08) against BTIG $25 (2026-07-24) — which reads as disagreement about the terminal model rather than a consolidated view.
• Demand sits downstream of CGT developer funding, so trial starts and biotech risk appetite drive the order book more than anything management controls. China is 2–3% of revenue, with local cryogenic-freezer manufacturing being stood up against tariff exposure (Q2 call, 2026-08-06).

Setup & Price Structure

Life-cycle: MATURING. The dating: the re-rate leg peaked in early June 2026 at a $16.57 52-week high; consensus converged down to $15.11 by 2026-07-08 with two holds added; BTIG's 2026-07-24 raise produced a gap-up on 2026-07-25; the 2026-08-06 print delivered a revenue beat, an EPS miss and an affirmed guide; two further target raises on 2026-08-07 left the close at $15.12. Fresh attention is arriving, participation is not widening into new highs. This is a well-known name still working, with moderating flow — not a fresh discovery, and not a broken structure.

Observable levels. The 2026 breakout shelf sits in the $13–14 zone; the 20-week EMA zone tracks near it. Below that, the 200-day average was near $11.07 when it was reclaimed on 2026-07-11 — the stock closed $15.12 on 2026-08-07, a wide gap above a rising long-term average, which is the extension to watch on any biotech-sentiment drawdown. Overhead, $16.57 is the level a re-acceleration has to clear, and it has capped price since early June.

Positioning observables, stated as observables. Three analyst target raises inside 15 days (2026-07-24, 2026-08-07 ×2) against a consensus that was $15.11 on 2026-07-08. Clustered officer selling on 2026-06-04 at a weighted $16.27, ~61% of the CFO's stake, unrecovered. RSI(14) 43.5 — no momentum extension either way. No earnings date inside the next 30 days; the print is behind, not ahead, which removes the event overhang and also removes the scheduled reason for new money to arrive before roughly November.

Catalyst Calendar (next 30 days)

• ~2026-08-14 (est.) — Q2 FY2026 Form 10-Q. Segment detail, share count, and the debt/preferred structure sitting against the $396.7M cash-and-short-term-investments line reported for 2026-06-30.
• ~2026-08-11 (est.) — post-print insider trading window reopens. Whether the June 2026 officer selling pattern repeats or stops is directly observable in EDGAR Form 4 filings.
• 2026-08-08 through ~2026-09-07 — no confirmed company event. As of 2026-08-08, the IR presentations page listed nothing scheduled after the Jefferies Global Healthcare Conference of 2026-06-03.
• by 2026-12-31 (est.) — the 11 possible BLA/MAA applications and up to five possible new therapy approvals management cited on 2026-08-06. Unscheduled and outside the 30-day window, but each approval converts a clinical account into higher-margin commercial volume.
• ~2026-11-05 (est.) — Q3 2026 print, the next scheduled binary (Q1 landed 2026-05-04, Q2 on 2026-08-06).

What Would Change Our Mind

The structure that would have to fail first is the $13–14 breakout shelf that has held since the spring leg; losing it would put the 2026 re-rate back to its origin and leave the 200-day average near $11.07 as the next reference. Concretely, a weekly close below $13 ends the read. Secondary conditions that would corroborate the break: commercial CGT revenue failing to reaccelerate above +15% YoY at the ~November Q3 print after Q2's +9%; adjusted EBITDA from continuing operations falling back below zero, making the +$0.4M Q2 crossover a one-quarter artifact rather than an inflection — one quarter is a sample of one, and the profitability leg currently rests entirely on it; or any cut to the affirmed $192–196M FY2026 band.

What would argue the other way, on the same evidentiary standard: Products revenue returning to growth after Q2's flat $21.0M, commercial CGT back above +15% YoY, and a weekly close above the $16.57 52-week high. Absent one of those, the higher-quality structure is a $13–14 retest that holds, and the case for chasing $15-handle prices into a catalyst vacuum is thin.

Correlation Notes

• Order flow is a derivative of CGT developer funding, so the name tracks biotech risk appetite (XBI) more closely than industrial logistics comparables. The 779-trial count at 2026-06-30 is the lagging record of funding decisions made quarters earlier.
• Within picks-and-shovels life-science tooling, the read-across runs to biostorage and bioprocessing suppliers — a sector-wide destocking or capex pause would show in Cryoport's Products line, which was already flat at $21.0M in Q2 2026, before it shows in Services.
• Regulatory flow is a shared driver: the January 2026 FDA loosening of CGT manufacturing requirements and the CMS Cell & Gene Therapy Access Model widen the trial-to-commercial funnel for the whole cohort, not for Cryoport alone.
• Tariff and China policy headlines carry limited direct revenue exposure here (2–3% of revenue, per the 2026-08-06 call) but move the freezer-manufacturing cost base and the broader tools complex together.
• Rates matter through the multiple: an operating-loss-making small cap with a large cash balance re-prices on discount-rate moves independent of any company datapoint.